These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 8302304

  • 1. Selegiline can mediate neuronal rescue rather than neuronal protection.
    Tatton WG.
    Mov Disord; 1993; 8 Suppl 1():S20-30. PubMed ID: 8302304
    [Abstract] [Full Text] [Related]

  • 2. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [Abstract] [Full Text] [Related]

  • 3. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D, Samantaray S, Mohanakumar KP.
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [Abstract] [Full Text] [Related]

  • 4. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism.
    Tatton WG, Greenwood CE.
    J Neurosci Res; 1991 Dec; 30(4):666-72. PubMed ID: 1686284
    [Abstract] [Full Text] [Related]

  • 5. Nigral degeneration in Parkinson's disease.
    Rinne JO.
    Mov Disord; 1993 Dec; 8 Suppl 1():S31-5. PubMed ID: 8302305
    [Abstract] [Full Text] [Related]

  • 6. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.
    Schmidt DE, Ebert MH, Lynn JC, Whetsell WO.
    J Neural Transm (Vienna); 1997 Dec; 104(8-9):875-85. PubMed ID: 9451719
    [Abstract] [Full Text] [Related]

  • 7. Deprenyl reduces the death of motoneurons caused by axotomy.
    Salo PT, Tatton WG.
    J Neurosci Res; 1992 Feb; 31(2):394-400. PubMed ID: 1374134
    [Abstract] [Full Text] [Related]

  • 8. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
    Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, Virley DJ.
    Br J Pharmacol; 2008 May; 154(1):226-33. PubMed ID: 18332857
    [Abstract] [Full Text] [Related]

  • 9. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM, Mohanakumar KP, Murphy DL, Chiueh CC.
    Ann N Y Acad Sci; 1994 Nov 17; 738():214-21. PubMed ID: 7832430
    [Abstract] [Full Text] [Related]

  • 10. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986 Nov 17; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 11. Neurotoxins and monoamine oxidase inhibition: new aspects.
    Finnegan KT.
    Mov Disord; 1993 Nov 17; 8 Suppl 1():S14-9. PubMed ID: 8302303
    [Abstract] [Full Text] [Related]

  • 12. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW, Hemrick-Luecke SK, Perry KW.
    J Pharmacol Exp Ther; 1988 Nov 17; 247(2):531-5. PubMed ID: 3141609
    [Abstract] [Full Text] [Related]

  • 13. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
    Youdim MB, Riederer P.
    Mov Disord; 1993 Nov 17; 8 Suppl 1():S8-13. PubMed ID: 8302308
    [Abstract] [Full Text] [Related]

  • 14. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE.
    Eur J Pharmacol; 1988 Feb 09; 146(2-3):313-8. PubMed ID: 3131149
    [Abstract] [Full Text] [Related]

  • 15. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
    Rothblat DS, Schneider JS.
    Brain Res; 1998 Jan 01; 779(1-2):226-30. PubMed ID: 9473679
    [Abstract] [Full Text] [Related]

  • 16. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition.
    Ansari KS, Yu PH, Kruck TP, Tatton WG.
    J Neurosci; 1993 Sep 01; 13(9):4042-53. PubMed ID: 8366359
    [Abstract] [Full Text] [Related]

  • 17. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.
    Thiffault C, Lamarre-Théroux L, Quirion R, Poirier J.
    Brain Res Mol Brain Res; 1997 Mar 01; 44(2):238-44. PubMed ID: 9073165
    [Abstract] [Full Text] [Related]

  • 18. Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity.
    Wu RM, Murphy DL, Chiueh CC.
    J Neural Transm Gen Sect; 1995 Mar 01; 100(1):53-61. PubMed ID: 8748663
    [Abstract] [Full Text] [Related]

  • 19. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium.
    Koutsilieri E, Chen TS, Rausch WD, Riederer P.
    Eur J Pharmacol; 1996 Jun 13; 306(1-3):181-6. PubMed ID: 8813631
    [Abstract] [Full Text] [Related]

  • 20. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
    Wu RM, Chen RC, Chiueh CC.
    Ann N Y Acad Sci; 2000 Jun 13; 899():255-61. PubMed ID: 10863544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.